COPD
MCID: PLM129
MIFTS: 75

Pulmonary Disease, Chronic Obstructive (COPD)

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 58 77 76 45 39
Chronic Obstructive Pulmonary Disease 39 12 77 38 30 15 17 3 64
Copd 58 12 76 44 3 64
Chronic Obstructive Lung Disease 12 76 15
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 58 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 30 6
Chronic Obstructive Airway Disease 12 74
Pulmonary Disease, Obstructive, Chronic, Susceptibility to 41
Severe Early-Onset Chronic Obstructive Pulmonary Disease 76
Chronic Obstructive Pulmonary Disease of Horses 74
Pulmonary Disease Chronic Obstructive 56
Upper Respiratory Infections 74
Common Cold 74
Cold 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3083
OMIM 58 606963
KEGG 38 H01714
MeSH 45 D029424
NCIt 51 C3199
SNOMED-CT 69 13645005

Summaries for Pulmonary Disease, Chronic Obstructive

MedlinePlus : 44 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to respiratory failure and lung disease, and has symptoms including tremor, fever and angina pectoris. An important gene associated with Pulmonary Disease, Chronic Obstructive is LINC00229 (Long Intergenic Non-Protein Coding RNA 229), and among its related pathways/superpathways are Spinal Cord Injury and Interleukin-4 and 13 signaling. The drugs Advair and Anoro Ellipta have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotype is chronic obstructive pulmonary disease.

OMIM : 58 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

UniProtKB/Swiss-Prot : 76 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 64 About chronic obstructive pulmonary disease: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time.COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms.Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 77 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1034)
# Related Disease Score Top Affiliating Genes
1 respiratory failure 33.2 CXCL8 ELANE PDE4A SERPINA1 TNF
2 lung disease 32.8 ADRB2 CXCL8 ELANE HMOX1 PDE4A SERPINA1
3 proteasome-associated autoinflammatory syndrome 1 31.9 CXCL8 ELANE PDE4A TNF
4 asthma 31.9 ADRB2 CXCL8 ELANE MMP1 PDE4A TNF
5 bronchiectasis 31.5 CXCL8 ELANE SERPINA1
6 pneumonia 31.3 CXCL8 ELANE TNF
7 haemophilus influenzae 31.1 CXCL8 TNF
8 pulmonary emphysema 31.1 ELANE HMOX1 MMP1 MMP12 SERPINA1
9 pulmonary fibrosis, idiopathic 31.0 CXCL8 ELANE MMP1 TNF
10 pulmonary edema 30.9 CXCL8 HMOX1 TNF
11 acute respiratory distress syndrome 30.9 CXCL8 ELANE TNF
12 cystic fibrosis 30.8 ADRB2 CXCL8 ELANE SERPINA1
13 periodontal disease 30.7 CXCL8 ELANE MMP1 TNF
14 vasculitis 30.7 ELANE SERPINA1 TNF
15 pulpitis 30.6 CXCL8 MMP1 TNF
16 alpha-1-antitrypsin deficiency 30.5 CXCL8 ELANE SERPINA1
17 bacterial infectious disease 30.5 CXCL8 ELANE TNF
18 bronchitis 30.5 CXCL8 ELANE SERPINA1 TNF
19 periodontitis 30.5 CXCL8 MMP1 TNF
20 dermatitis, atopic 30.4 CXCL8 PDE4A TNF
21 osteogenic sarcoma 30.4 FENDRR MEG3 TUG1
22 pneumoconiosis 30.3 CXCL8 SERPINA1 TNF
23 myeloma, multiple 30.2 CXCL8 MEG3 TNF TUG1
24 synovitis 30.0 CXCL8 MMP1 TNF
25 bladder cancer 29.9 MEG3 SNHG5 TINCR TNF TUG1
26 familial cold autoinflammatory syndrome 1 12.7
27 familial cold autoinflammatory syndrome 12.7
28 cold urticaria 12.7
29 familial cold autoinflammatory syndrome 3 12.7
30 cold agglutinin disease 12.5
31 cold-induced sweating syndrome 12.5
32 paroxysmal cold hemoglobinuria 12.5
33 crisponi/cold-induced sweating syndrome 1 12.5
34 familial cold autoinflammatory syndrome 4 12.5
35 familial cold autoinflammatory syndrome 2 12.5
36 crisponi/cold-induced sweating syndrome 2 12.4
37 crisponi/cold-induced sweating syndrome 3 12.4
38 cold-induced sweating syndrome including crisponi syndrome 12.1
39 cryohydrocytosis 11.9
40 perniosis 11.8
41 raynaud disease 11.8
42 coloboma, ocular, autosomal dominant 11.8
43 paramyotonia congenita of von eulenburg 11.7
44 canomad syndrome 11.5
45 nasopharyngitis 11.5
46 cryoglobulinemia 11.4
47 warm antibody hemolytic anemia 11.4
48 pleural disease 11.3
49 multifocal atrial tachycardia 11.3
50 hyperkalemic periodic paralysis 11.3

Comorbidity relations with Pulmonary Disease, Chronic Obstructive via Phenotypic Disease Network (PDN):


Bronchitis Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

33
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 33 HP:0006510

Clinical features from OMIM:

606963

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


tremor, fever, angina pectoris, pruritus, tinnitus, snoring, rhinorrhea, sore throat, coughing, vertigo/dizziness, equilibration disorder, catarrh, upper respiratory tract inflammation

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMedHealth treatment related to Pulmonary Disease, Chronic Obstructive: 64

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease.The goals of COPD treatment include:Relieving your symptomsSlowing the progress of the diseaseImproving your exercise tolerance (your ability to stay active)Preventing and treating complicationsImproving your overall healthTo assist with your treatment, your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Advair 19 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
2
Anoro Ellipta 19 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
3
Arcapta 19 INDACATEROL MALEATE Novartis July 2011
4
Breo Ellipta 19 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GlaxoSmithKline May 2013
5
Brovana 19 ARFORMOTEROL TARTRATE Sepracor in October 2006
6
Daliresp 19 ROFLUMILAST Forest Pharmaceuticals February 2011
7
DuoNeb 19 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
8
Foradil Aerolizer 19 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Incruse Ellipta 19 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
10
Rayos 19 PREDNISONE Horizon Pharma July of 2012
11
Spiriva HandiHaler 19 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
12
Stiolto Respimat 19 OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE Boehringer Ingelheim May 2015
13
Striverdi Respimat 19 OLODATEROL HYDROCHLORIDE Boehringer Ingelheim July 2014
14
Tudorza Pressair 19 ACLIDINIUM BROMIDE Forest Laboratories July 2012
15
Utibron Neohaler 19 GLYCOPYRROLATE ; INDACATEROL MALEATE Novartis October 2015
16
Xopenex 19 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 703)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83905-01-5 55185 447043
2
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718 468682
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
5
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 78919-13-8 6443959
6
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
8
Terbutaline Approved Phase 4,Phase 3,Not Applicable 23031-25-6 5403
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
10
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
11
Iron Approved, Experimental Phase 4,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
12
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
13
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
14
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
15
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
16
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232 657309
17
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 564-25-0 54671203
18
Sultamicillin Approved, Investigational Phase 4 76497-13-7
19
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
20
Sulbactam Approved Phase 4 68373-14-8
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
22
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
25
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
26
Tazobactam Approved Phase 4,Not Applicable 89786-04-9 123630
27
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
28
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
29
Cefuroxime Approved Phase 4,Phase 3 55268-75-2 5361202 5479529
30
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
31
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
32
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
33
Theophylline Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-55-9 2153
34
Fenoterol Approved, Investigational Phase 4,Phase 3,Not Applicable 13392-18-2 3343
35
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
36
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
37
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72332-33-3 688561
38
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
39
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 616-91-1 12035
40
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 942 89594
41
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
42
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
43
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
44
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
45
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
46
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
47
Liraglutide Approved Phase 4 204656-20-2 44147092
48
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
49
Olodaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 868049-49-4
50
Regadenoson Approved, Investigational Phase 4,Early Phase 1 313348-27-5 219024

Interventional clinical trials:

(show top 50) (show all 3420)
# Name Status NCT ID Phase Drugs
1 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
2 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
5 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
6 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
7 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
8 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
9 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
10 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
11 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
12 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
13 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
14 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
15 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
16 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
17 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
18 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
19 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
20 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
21 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
22 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
23 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
24 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
25 Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD Unknown status NCT01892488 Phase 4 Sultamicillin;Placebo
26 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
27 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
28 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
29 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
30 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
31 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
32 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
33 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
34 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
35 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
36 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
37 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
38 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
39 A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis Unknown status NCT03132610 Phase 4 andrographolide sulfonate;andrographolide sulfonate simulation
40 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Recruiting NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
41 Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease Recruiting NCT03551197 Phase 4 Budesonide and formoterol bid
42 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
43 Effects of Liraglutide in Chronic Obstructive Pulmonary Disease Recruiting NCT03466021 Phase 4 Liraglutide;Placebo
44 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
45 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00984659 Phase 4 Fluticasone propionate/salmeterol combination product;Salmeterol;Placebo
46 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate
47 Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01397890 Phase 4 Budesonide/formoterol (Symbicort® Turbuhaler®);Tiotropium (SpirivaTM)
48 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations Completed NCT00115492 Phase 4 Fluticasone Propionate/Salmeterol Combination Product;Salmeterol
49 ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. Completed NCT00144911 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product
50 Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02786927 Phase 4 Placebo ELLIPTA device;Placebo capsules for use in HANDIHALER device

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 30 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 30

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

42
Lung, Testes, Heart, Endothelial, Bone, Neutrophil, Smooth Muscle

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 5721)
# Title Authors Year
1
β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. ( 30835781 )
2019
2
Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. ( 30680495 )
2019
3
Left ventricular global longitudinal strain and long-term prognosis in patients with chronic obstructive pulmonary disease after acute myocardial infarction. ( 29529225 )
2019
4
Accelerated lung aging and chronic obstructive pulmonary disease. ( 30735057 )
2019
5
Chronic Obstructive Pulmonary Disease as a Main Factor of Premature Aging. ( 30781849 )
2019
6
Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary? ( 30630519 )
2019
7
Inflammatory Cytokines and T-Lymphocyte Subsets in Serum and Sputum in Patients with Bronchial Asthma and Chronic Obstructive Pulmonary Disease. ( 30908476 )
2019
8
Modern Innovative Solutions to Improve Outcomes in Asthma, Breathlessness, and Chronic Obstructive Pulmonary Disease (MISSION ABC): Protocol for a Mixed-Methods Study. ( 30882359 )
2019
9
Availability and affordability of medicines and diagnostic tests recommended for management of asthma and chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. ( 30899279 )
2019
10
NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma. ( 30804927 )
2019
11
Medicaid Expansion and Mechanical Ventilation in Asthma, Chronic Obstructive Pulmonary Disease, and Heart Failure. ( 30811951 )
2019
12
Inhaled Glucocorticoid with or without Tiotropium Bromide for Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. ( 30823952 )
2019
13
Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease. ( 30759444 )
2019
14
Genetic profiling for disease stratification in chronic obstructive pulmonary disease and asthma. ( 30762612 )
2019
15
Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. ( 30782562 )
2019
16
Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease. ( 30789018 )
2019
17
Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease-A Next-Generation Sequencing-Guided Bioinformatic Approach. ( 30696075 )
2019
18
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. ( 30657422 )
2019
19
Association between asthma/chronic obstructive pulmonary disease overlap syndrome and healthcare utilization among the US adult population. ( 30612470 )
2019
20
Oxidative stress and macrophages: driving forces behind exacerbations of asthma and chronic obstructive pulmonary disease? ( 30520687 )
2019
21
The many faces of asthma-chronic obstructive pulmonary disease overlap. ( 30461532 )
2019
22
Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis. ( 30314929 )
2019
23
Prevalence of atrial fibrillation in hospital encounters with end-stage chronic obstructive pulmonary disease on home oxygen: National trends in the United States. ( 30684473 )
2019
24
Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms. ( 30446289 )
2019
25
Prevalence of Comorbid Chronic Obstructive Pulmonary Disease in Individuals Suffering from Schizophrenia and Bipolar Disorder: A Systematic Review. ( 30714418 )
2019
26
Improved quality of life associated with long-term use of guaifenesin in a patient with chronic obstructive pulmonary disease (COPD) & stable chronic bronchitis: A case report. ( 30450278 )
2019
27
Quantitative Assessment of Mucociliary Clearance in Smokers with Mild-to-Moderate Chronic Obstructive Pulmonary Disease and Chronic Bronchitis from Planar Radionuclide Imaging Using the Change in Penetration Index. ( 30848685 )
2019
28
Brooke-Spiegler syndrome with chronic obstructive pulmonary disease and chronic sinusitis. ( 30628115 )
2019
29
Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. ( 30132922 )
2019
30
Effort Oxygen Saturation and Effort Heart Rate to Detect Exacerbations of Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. ( 30621152 )
2019
31
Mid-Term Reproducibility of Chest MRI in Adults with Clinically Stable Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. ( 30875236 )
2019
32
Chronic Obstructive Pulmonary Disease and Risk of Dementia and Mortality in Lower to Middle Income Countries. ( 30714954 )
2019
33
Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. ( 30838649 )
2019
34
Serum testosterone depression as a factor influencing the general condition in chronic obstructive pulmonary disease patients. ( 30843676 )
2019
35
Relationships Between Social/Emotional Support and Quality of Life, Depression and Disability in Patients With Chronic Obstructive Pulmonary Disease: An Analysis Based on Propensity Score Matching. ( 30773583 )
2019
36
Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: a potential mechanism underlying the cross talk between lung and brain. ( 30738183 )
2019
37
Investigation of the effect of kinesiotaping on the respiratory function and depression in male patients with chronic obstructive pulmonary disease: a prospective, randomized, controlled, and single-blind study. ( 30739540 )
2019
38
High Prevalence of Diabetes Mellitus in a Cohort of Patients with Chronic Obstructive Pulmonary Disease in Trinidad, West Indies. ( 30664421 )
2019
39
Which Shall I Choose? Lung Transplantation Listing Preference for Individuals with Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease. ( 30707065 )
2019
40
Benefits of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease and interstitial lung disease with the same dyspnea severity. ( 30755382 )
2019
41
Does chronic obstructive pulmonary disease relate to poor prognosis in patients with lung cancer?: A meta-analysis. ( 30882673 )
2019
42
End-of-life care for patients with advanced lung cancer and chronic obstructive pulmonary disease - survey among Polish pulmonologists. ( 30833536 )
2019
43
Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. ( 30807641 )
2019
44
Patients and informal caregivers' experiences of burden of treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a systematic review and synthesis of qualitative research. ( 30813114 )
2019
45
Quantitative computed tomography for predicting cardiopulmonary complications after lobectomy for lung cancer in patients with chronic obstructive pulmonary disease. ( 30796609 )
2019
46
Lung cancer symptom appraisal among people with Chronic Obstructive Pulmonary Disease: A qualitative interview study. ( 30693608 )
2019
47
Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer, A Point of View. ( 30706659 )
2019
48
End-of-Life Health Care Utilization Between Chronic Obstructive Pulmonary Disease and Lung Cancer Patients. ( 30708124 )
2019
49
Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease. ( 30642451 )
2019
50
Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. ( 30605063 )
2019